R01NS129156
Project Grant
Overview
Grant Description
Minimally Invasive Tissue Sampling to Evaluate HIV-Associated Meningitis in Zambia
There is an urgent need to establish the etiology and improve diagnostics of HIV-associated meningitis in countries like Zambia, given the high rates of mortality. A lack of post-mortem studies in low and middle-income countries prevents in-depth studies on tissue from confirmed meningitis patients.
Central nervous system (CNS) co-infection frequently occurs in HIV-associated meningitis, but no study has investigated its impact on mortality. Tuberculous meningitis (TBM), one of the most common causes of HIV-associated meningitis, lacks a sensitive cerebrospinal fluid (CSF) lateral flow assay to serve as a simple point of care diagnostic. The best candidate lipid biomarker for a point of care assay has not been established.
Best practices and expertise for CSF and brain tissue handling, processing, and analyses are also lacking in many sub-Saharan African countries. Our long-term goal is to establish causes of mortality, optimal diagnostic biomarkers, and laboratory expertise to improve outcomes of HIV-associated meningitis.
We will test the following set of specific aims:
Aim 1) Establish comprehensive etiologies of HIV-associated meningitis.
Aim 2) To improve CSF diagnostics for patients with HIV-associated meningitis in resource-limited settings, we will explore more optimal candidate CSF lipid biomarkers to diagnose TBM.
Aim 3) Strengthen laboratory services to improve the diagnosis of meningitis.
The approach is innovative because it systematically uses post-mortem tissue from an endemic setting to evaluate HIV-associated meningitis. The proposed research is significant because it allows us to establish etiologies and diagnostic biomarkers in HIV-associated meningitis while improving the laboratory capability in Zambia to diagnose CNS infections. These findings will have an important impact on the clinical management of meningitis and provide specific evidence to guide empiric treatment of patients in the future.
There is an urgent need to establish the etiology and improve diagnostics of HIV-associated meningitis in countries like Zambia, given the high rates of mortality. A lack of post-mortem studies in low and middle-income countries prevents in-depth studies on tissue from confirmed meningitis patients.
Central nervous system (CNS) co-infection frequently occurs in HIV-associated meningitis, but no study has investigated its impact on mortality. Tuberculous meningitis (TBM), one of the most common causes of HIV-associated meningitis, lacks a sensitive cerebrospinal fluid (CSF) lateral flow assay to serve as a simple point of care diagnostic. The best candidate lipid biomarker for a point of care assay has not been established.
Best practices and expertise for CSF and brain tissue handling, processing, and analyses are also lacking in many sub-Saharan African countries. Our long-term goal is to establish causes of mortality, optimal diagnostic biomarkers, and laboratory expertise to improve outcomes of HIV-associated meningitis.
We will test the following set of specific aims:
Aim 1) Establish comprehensive etiologies of HIV-associated meningitis.
Aim 2) To improve CSF diagnostics for patients with HIV-associated meningitis in resource-limited settings, we will explore more optimal candidate CSF lipid biomarkers to diagnose TBM.
Aim 3) Strengthen laboratory services to improve the diagnosis of meningitis.
The approach is innovative because it systematically uses post-mortem tissue from an endemic setting to evaluate HIV-associated meningitis. The proposed research is significant because it allows us to establish etiologies and diagnostic biomarkers in HIV-associated meningitis while improving the laboratory capability in Zambia to diagnose CNS infections. These findings will have an important impact on the clinical management of meningitis and provide specific evidence to guide empiric treatment of patients in the future.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Boston,
Massachusetts
022155400
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 306% from $472,160 to $1,916,441.
Beth Israel Deaconess Medical Center was awarded
Minimally Invasive Sampling for HIV Meningitis in Zambia
Project Grant R01NS129156
worth $1,916,441
from the National Institute of Neurological Disorders and Stroke in June 2022 with work to be completed primarily in Boston Massachusetts United States.
The grant
has a duration of 4 years 10 months and
was awarded through assistance program 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
The Project Grant was awarded through grant opportunity Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional).
Status
(Ongoing)
Last Modified 6/20/24
Period of Performance
6/15/22
Start Date
4/30/27
End Date
Funding Split
$1.9M
Federal Obligation
$0.0
Non-Federal Obligation
$1.9M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R01NS129156
Transaction History
Modifications to R01NS129156
Additional Detail
Award ID FAIN
R01NS129156
SAI Number
R01NS129156-4204920993
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NQ00 NIH NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Funding Office
75NQ00 NIH NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Awardee UEI
C1CPANL3EWK4
Awardee CAGE
4B998
Performance District
MA-07
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of Neurological Disorders and Stroke, National Institutes of Health, Health and Human Services (075-0886) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,187,596 | 98% |
Modified: 6/20/24